Rocket Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Rocket Pharmaceuticals (RCKT) to Underweight from Neutral without a price target The firm believes Rocket has an “interesting” gene therapy portfolio primarily aimed at rare, genetically driven heart conditions. While the shares as ascribing minimal pipeline credit, the setup is challenging for upside over the next 12 months, the analyst tells investors in a research note. JPMorgan sees risks with Rocket’s lead program in Danon disease.